Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Short Interest Up 31.8% in March

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Get Free Report) was the recipient of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 1,740,000 shares, a growth of 31.8% from the February 29th total of 1,320,000 shares. Currently, 9.6% of the shares of the company are sold short. Based on an average daily volume of 212,500 shares, the short-interest ratio is currently 8.2 days.

Institutional Trading of Syros Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Two Sigma Investments LP raised its holdings in shares of Syros Pharmaceuticals by 30.0% during the first quarter. Two Sigma Investments LP now owns 13,600 shares of the company's stock valued at $36,000 after acquiring an additional 3,139 shares during the period. Renaissance Technologies LLC increased its stake in Syros Pharmaceuticals by 8.0% in the 4th quarter. Renaissance Technologies LLC now owns 47,235 shares of the company's stock valued at $170,000 after buying an additional 3,500 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Syros Pharmaceuticals by 85.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 22,550 shares of the company's stock valued at $61,000 after buying an additional 10,400 shares during the period. LPL Financial LLC increased its stake in Syros Pharmaceuticals by 13.1% in the 2nd quarter. LPL Financial LLC now owns 94,075 shares of the company's stock valued at $296,000 after buying an additional 10,886 shares during the period. Finally, Shay Capital LLC increased its stake in Syros Pharmaceuticals by 87.3% in the 2nd quarter. Shay Capital LLC now owns 26,426 shares of the company's stock valued at $83,000 after buying an additional 12,317 shares during the period. 91.47% of the stock is currently owned by institutional investors.

Syros Pharmaceuticals Price Performance

Shares of NASDAQ SYRS traded down $0.49 during midday trading on Friday, reaching $5.35. The company's stock had a trading volume of 318,254 shares, compared to its average volume of 190,065. The company has a current ratio of 3.95, a quick ratio of 4.31 and a debt-to-equity ratio of 2.07. The company has a 50 day moving average price of $6.84 and a 200 day moving average price of $5.08. Syros Pharmaceuticals has a one year low of $2.09 and a one year high of $8.17. The company has a market cap of $112.71 million, a price-to-earnings ratio of -0.93 and a beta of 1.79.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of Syros Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.